A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
MOMA Therapeutics
Kivu Bioscience Inc.
University of California, San Francisco
Evopoint Biosciences Inc.
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
National Cancer Institute (NCI)
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
Revolution Medicines, Inc.
Bayer
AstraZeneca
National Institutes of Health Clinical Center (CC)
AstraZeneca
Imperial College London
Unidade Local de Saúde São João
City of Hope Medical Center
Institut Paoli-Calmettes
Filamon LTD
AstraZeneca
NeoImmuneTech
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Rutgers, The State University of New Jersey
National Institutes of Health Clinical Center (CC)
Aveni Foundation
Psyence Australia Pty Ltd
ViroMissile, Inc.
Dana-Farber Cancer Institute
Sichuan Enray Pharmaceutical Sciences Company
Duke University
A2 Biotherapeutics Inc.
AstraZeneca
M.D. Anderson Cancer Center
Arvinas Inc.
Essen Biotech
National Institutes of Health Clinical Center (CC)
Azienda Ospedaliero-Universitaria di Parma
Dana-Farber Cancer Institute
A2 Biotherapeutics Inc.